Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Alexza’s Inhaled Antipsychotic May Pose Lung Risks, FDA Says
Dec. 12, 2011
Alexza Pharmaceuticals’ inhaled antipsychotic drug may pose lung risks, according to U.S. regulators considering whether to approve the treatment for sale.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing